Svein I Johannessen

Summary

Affiliation: National Centre for Epilepsy
Country: Norway

Publications

  1. doi request reprint Antiepileptic drug treatment of children at a referral centre for epilepsy--does admission make a difference?
    Elisif Rytter
    National Centre for Epilepsy, Sandvika, Division of Clinical Neuroscience, Rikshospitalet University Hospital, Oslo, Norway
    Seizure 18:573-9. 2009
  2. ncbi request reprint Can pharmacokinetic variability be controlled for the patient's benefit? The place of TDM for new AEDs
    Svein I Johannessen
    The National Center for Epilepsy, Sandvika, Norway
    Ther Drug Monit 27:710-3. 2005
  3. ncbi request reprint Therapeutic drug monitoring of the newer antiepileptic drugs
    Svein I Johannessen
    The National Center for Epilepsy, Sandvika, Norway, Carlo Besta, Milan, Italy
    Ther Drug Monit 25:347-63. 2003
  4. ncbi request reprint Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?
    Svein I Johannessen
    The National Center for Epilepsy, Sandvika, Norway
    Clin Pharmacokinet 45:1061-75. 2006
  5. ncbi request reprint Valproate: past, present, and future
    Cecilie U Johannessen
    University College of Oslo, Oslo, Norway
    CNS Drug Rev 9:199-216. 2003
  6. ncbi request reprint [Oral contraceptives in women with epilepsy]
    Elisif Rytter
    Spesialsykehuset for epilepsi, G F Henriksens vei 23, Sandvika
    Tidsskr Nor Laegeforen 123:1674-5. 2003
  7. ncbi request reprint [Seizure exacerbation caused by antiepileptic drugs]
    Karl O Nakken
    Epilepsisenteret SSE, Sandvika, Posboks 53, 1306 Baerum postterminal
    Tidsskr Nor Laegeforen 128:2052-5. 2008
  8. doi request reprint Value of therapeutic drug monitoring in epilepsy
    Svein I Johannessen
    The National Center for Epilepsy, Sandvika, Division of Clinical Neuroscience, Rikshospitalet University Hospital, Oslo, POB 53, N 1306 BPT, Norway
    Expert Rev Neurother 8:929-39. 2008
  9. ncbi request reprint Levetiracetam concentrations in serum and in breast milk at birth and during lactation
    Svein I Johannessen
    The National Center for Epilepsy, Sandvika, Norway
    Epilepsia 46:775-7. 2005
  10. ncbi request reprint Management of focal-onset seizures: an update on drug treatment
    Svein I Johannessen
    The National Center for Epilepsy, Sandvika, Norway
    Drugs 66:1701-25. 2006

Detail Information

Publications22

  1. doi request reprint Antiepileptic drug treatment of children at a referral centre for epilepsy--does admission make a difference?
    Elisif Rytter
    National Centre for Epilepsy, Sandvika, Division of Clinical Neuroscience, Rikshospitalet University Hospital, Oslo, Norway
    Seizure 18:573-9. 2009
    ..To study the antiepileptic drug treatment of children at a referral centre for epilepsy, including a follow-up study three months after discharge...
  2. ncbi request reprint Can pharmacokinetic variability be controlled for the patient's benefit? The place of TDM for new AEDs
    Svein I Johannessen
    The National Center for Epilepsy, Sandvika, Norway
    Ther Drug Monit 27:710-3. 2005
    ..The primary role of TDM for both the newer and established AEDs is to identify an individual's optimum concentration and thus establish a reference value in that patient...
  3. ncbi request reprint Therapeutic drug monitoring of the newer antiepileptic drugs
    Svein I Johannessen
    The National Center for Epilepsy, Sandvika, Norway, Carlo Besta, Milan, Italy
    Ther Drug Monit 25:347-63. 2003
    ..Although routine monitoring in general cannot be recommended at present, measurements of some of the drugs is undoubtedly of help with individualization of treatment in selected cases in a particular clinical setting...
  4. ncbi request reprint Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?
    Svein I Johannessen
    The National Center for Epilepsy, Sandvika, Norway
    Clin Pharmacokinet 45:1061-75. 2006
    ..The purpose of the present review is to discuss individually the potential value of TDM of these newer AEDs, with emphasis on pharmacokinetic variability...
  5. ncbi request reprint Valproate: past, present, and future
    Cecilie U Johannessen
    University College of Oslo, Oslo, Norway
    CNS Drug Rev 9:199-216. 2003
    ..Furthermore, the toxicity of VPA, both regarding commonly occurring side effects and potential idiosyncratic reactions are described. Derivatives of VPA with improved efficacy and tolerability are in development...
  6. ncbi request reprint [Oral contraceptives in women with epilepsy]
    Elisif Rytter
    Spesialsykehuset for epilepsi, G F Henriksens vei 23, Sandvika
    Tidsskr Nor Laegeforen 123:1674-5. 2003
  7. ncbi request reprint [Seizure exacerbation caused by antiepileptic drugs]
    Karl O Nakken
    Epilepsisenteret SSE, Sandvika, Posboks 53, 1306 Baerum postterminal
    Tidsskr Nor Laegeforen 128:2052-5. 2008
    ..In certain types of epilepsy, antiepileptic drugs can exacerbate the disease instead of improving it...
  8. doi request reprint Value of therapeutic drug monitoring in epilepsy
    Svein I Johannessen
    The National Center for Epilepsy, Sandvika, Division of Clinical Neuroscience, Rikshospitalet University Hospital, Oslo, POB 53, N 1306 BPT, Norway
    Expert Rev Neurother 8:929-39. 2008
    ..The reference range is a range of drug concentrations quoted by laboratories and is not a therapeutic range. Emphasis should be placed on the concept of an individual therapeutic concentration...
  9. ncbi request reprint Levetiracetam concentrations in serum and in breast milk at birth and during lactation
    Svein I Johannessen
    The National Center for Epilepsy, Sandvika, Norway
    Epilepsia 46:775-7. 2005
    ..To study the pharmacokinetics of levetiracetam (LEV) at birth, during lactation, and in the nursed infant...
  10. ncbi request reprint Management of focal-onset seizures: an update on drug treatment
    Svein I Johannessen
    The National Center for Epilepsy, Sandvika, Norway
    Drugs 66:1701-25. 2006
    ..Among the newer AEDs, lamotrigine, gabapentin, topiramate and oxcarbazepine have obtained monotherapy indication in many countries. The higher costs of the newer AEDs may inhibit their wider use, especially in poorer countries...
  11. ncbi request reprint A paradoxical effect of levetiracetam may be seen in both children and adults with refractory epilepsy
    Karl O Nakken
    The National Centre for Epilepsy, Sandvika, Norway
    Seizure 12:42-6. 2003
    ..By using a lower initial dose and a slower dose escalation than recommended by the manufacturer, a paradoxical effect may perhaps be avoided. In children, doses >20 mgkg(-1) per day should be introduced with caution...
  12. pmc Antiepileptic drug interactions - principles and clinical implications
    Svein I Johannessen
    The National Center for Epilepsy, Sandvika, and Department of Pharmacology, Oslo University Hospital, Oslo, Norway
    Curr Neuropharmacol 8:254-67. 2010
    ..Level 3 refers to interactions where dosage adjustments are usually not necessary. Updated knowledge regarding drug interactions is important to predict the potential for harmful or lacking effects involving AEDs...
  13. ncbi request reprint Interlaboratory variability in the quantification of new generation antiepileptic drugs based on external quality assessment data
    John Williams
    Subcommission on Therapeutic Drug Monitoring and Pharmacokinetics, ILAE Commission on Therapeutic Strategies, Department of Pharmacology, Therapeutics and Toxicology, University of Wales College of Medicine, Heath Park, Cardiff, Wales
    Epilepsia 44:40-5. 2003
    ..To assess interlaboratory variability in the determination of serum levels of new antiepileptic drugs (AEDs)...
  14. ncbi request reprint [Levetiracetam in the treatment of epilepsy]
    Theresa Mariero Klees
    Avdeling for nevrologi og klinisk nevrofysiologi, St Olavs Hospital, 7006 Trondheim
    Tidsskr Nor Laegeforen 123:1539-41. 2003
    ..A proportion of patients with epilepsy are still without seizure control. This open study aims to evaluate the effect and tolerability in consecutive patients treated with the new antiepileptic drug levetiracetam...
  15. ncbi request reprint Serum concentrations and effects of gabapentin and vigabatrin: observations from a dose titration study
    Martin Lindberger
    Department of Neurology, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden
    Ther Drug Monit 25:457-62. 2003
    ..Hence, with the present study design we were unable to identify specific target ranges of GBP and VGB serum concentrations...
  16. doi request reprint Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies
    Philip N Patsalos
    Institute of Neurology The National Hospital for Neurology and Neurosurgery, London and The Chalfont Centre for Epilepsy, Chalfont St Peter, United Kingdom
    Epilepsia 49:1239-76. 2008
    ..g., in pregnancy, or when an interacting drug is added or removed); (6) to guide dose adjustments for AEDs with dose-dependent pharmacokinetics, particularly phenytoin...
  17. ncbi request reprint Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII)
    Meir Bialer
    Department of Pharmaceutics, Faculty of Medicine, School of Pharmacy and David R Bloom Center for Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel
    Epilepsy Res 61:1-48. 2004
    ....
  18. ncbi request reprint The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come?
    Emilio Perucca
    Clinical Pharmacology Unit, University of Pavia, Pavia, Italy
    Epileptic Disord 5:S17-26. 2003
    ..Although its half-life is relatively short (6 to 8 hours), its duration of action is longer than anticipated from its pharmacokinetics in plasma, and a twice-daily dosing regimen is adequate to produce the desired response...
  19. ncbi request reprint Levetiracetam in adult patients with and without learning disability: focus on behavioral adverse effects
    Eylert Brodtkorb
    Department of Neurology, St Olav s Hospital, University Hospital, Trondheim, Norway
    Epilepsy Behav 5:231-5. 2004
    ..However, behavioral problems are more frequent in patients with LD, whereas the tendency toward seizure increase is not enhanced...
  20. ncbi request reprint Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII)
    Meir Bialer
    Department of Pharmaceutics, School of Pharmacy, David R Bloom Center for Pharmacy, The Hebrew University of Jerusalem, 91120 Jerusalem, Israel
    Epilepsy Res 73:1-52. 2007
    ....
  21. ncbi request reprint Medical risks in epilepsy: a review with focus on physical injuries, mortality, traffic accidents and their prevention
    Torbjorn Tomson
    Department of Clinical Neuroscience, Karolinska Institute, SE 171 76 Stockholm, Sweden
    Epilepsy Res 60:1-16. 2004
    ..Moreover, the preventive measures in legislation may be ignored by many people with epilepsy...
  22. ncbi request reprint Clinical use of antiepileptic drugs at a referral centre for epilepsy
    Cecilie Johannessen Landmark
    Department of Pharmacy, Faculty of Health Sciences, Oslo University College, Pilestredet 52, N 0167 Oslo, Norway
    Seizure 16:356-64. 2007
    ..The purpose of this study was to investigate how antiepileptic drugs (AEDs) are used at the centre and compare it with the total consumption in the country and international guidelines regarding clinical use of AEDs...